Home › Athersys, Inc. (ATHX) Upgraded to Buy at Zacks Investment Research
 

Keywords :   


Athersys, Inc. (ATHX) Upgraded to Buy at Zacks Investment Research

2016-03-12 01:37:03| Biotech - Topix.net

The brokerage presently has a $2.50 price target on the biopharmaceutical company's stock. Zacks Investment Research 's price objective would indicate a potential upside of 14.68% from the company's current price.

Tags: buy research investment upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Still no sign of herd rebuilding
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
More »